NYSEAMERICAN:CLDI Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis $1.03 -0.02 (-1.43%) As of 01:28 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Calidi Biotherapeutics Stock (NYSEAMERICAN:CLDI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Calidi Biotherapeutics alerts:Sign Up Key Stats Today's Range$1.03▼$1.0750-Day Range$1.05▼$1.8952-Week Range$1.00▼$27.84Volume30,295 shsAverage Volume215,818 shsMarket Capitalization$2.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company developing stem cell-based therapies designed to improve the delivery and effectiveness of cancer treatments. The company’s approach uses allogeneic stem cells as protective carriers that can transport therapeutic agents into tumors while helping shield those agents from the body’s immune system. Calidi’s technology platforms include NeuroNova, which is based on neural stem cells, and SuperNova, which uses engineered allogeneic stem cells. Its development programs have focused on potential treatments for solid tumors, including recurrent glioblastoma, and are intended to support the delivery of oncolytic viruses and other anti-cancer payloads directly to tumor sites. Founded in 2014 and headquartered in San Diego, California, Calidi Biotherapeutics became a publicly traded company through a business combination in 2023 and trades on the NYSE American under the symbol CLDI. The company’s programs remain in clinical development, and its research and potential commercial activities are focused on oncology applications.AI Generated. May Contain Errors. Read More Calidi Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreCLDI MarketRank™: Calidi Biotherapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Calidi Biotherapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Calidi Biotherapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Calidi Biotherapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalidi Biotherapeutics has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.21% of the float of Calidi Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverCalidi Biotherapeutics has a short interest ratio ("days to cover") of 6.23.Change versus previous monthShort interest in Calidi Biotherapeutics has recently decreased by 1.45%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCalidi Biotherapeutics does not currently pay a dividend.Dividend GrowthCalidi Biotherapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Calidi Biotherapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Calidi Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.30% of the stock of Calidi Biotherapeutics is held by insiders.Percentage Held by Institutions12.53% of the stock of Calidi Biotherapeutics is held by institutions.Read more about Calidi Biotherapeutics' insider trading history. Receive CLDI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calidi Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLDI Stock News HeadlinesCalidi Put On Notice By NYSE For Non-Compliance In Stockholders' Equity; Shares Fall By 5%September 26, 2026 | rttnews.comCalidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity DeficiencySeptember 25, 2026 | markets.businessinsider.comElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.October 6 at 1:00 AM | American Hartford Gold (Ad)Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity DeficiencySeptember 25, 2026 | globenewswire.comCalidi Biotherapeutics Announces Registered Direct Stock OfferingSeptember 22, 2026 | tipranks.comCalidi Biotherapeutics Unveils $1.2 Mln Offering Of Shares; Stock UpSeptember 17, 2026 | rttnews.comCalidi Biotherapeutics Announces $1.2 Million Registered Direct OfferingSeptember 17, 2026 | markets.businessinsider.comCalidi Biotherapeutics Announces $1.2 Million Registered Direct OfferingSeptember 17, 2026 | globenewswire.comSee More Headlines CLDI Stock Analysis - Frequently Asked Questions How have CLDI shares performed this year? Calidi Biotherapeutics' stock was trading at $18.72 at the beginning of the year. Since then, CLDI stock has decreased by 94.4% and is now trading at $1.0460. How were Calidi Biotherapeutics' earnings last quarter? Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) announced its earnings results on Thursday, August, 13th. The company reported ($2.94) EPS for the quarter. When did Calidi Biotherapeutics' stock split? Shares of Calidi Biotherapeutics reverse split before market open on Monday, July 15th 2024.The 1-10 reverse split was announced on Monday, July 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Calidi Biotherapeutics? Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today10/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (13m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CLDI's financial health is in the Red zone, according to TradeSmith. CLDI has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:CLDI Previous SymbolNYSE:CLDI CIK1855485 Webcalidibio.com Phone858-794-9600FaxN/AEmployees29Year Founded2014Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.91 million Net MarginsN/A Pretax MarginN/A Return on Equity-368.29% Return on Assets-176.58% Debt Debt-to-Equity Ratio0.24 Current Ratio1.68 Quick Ratio1.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.33 per share Price / Book0.12Miscellaneous Outstanding Shares2,660,000Free Float2,546,000Market Cap$2.75 million OptionableN/A Beta1.33 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSEAMERICAN:CLDI) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc (OTCQB: VDTA) is building beneath the AI boom, targeting GPU hardware and financing, managed...Trading Wire | SponsoredNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
